Literature DB >> 24184665

Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia.

Telma Martins1, Rui Vitorino2, Daniel Moreira-Gonçalves3, Francisco Amado4, José Alberto Duarte3, Rita Ferreira1.   

Abstract

Cardiac cachexia (CC) affects a large proportion of patients with chronic heart failure, a major public health issue in western countries. The pathophysiology of CC is complex and multifactorial, resulting from several factors interacting in a complex system with metabolic, immune and neurohormonal consequences, triggered to protect the heart and the circulation from damage. Despite the adverse clinical effects, CC diagnosis is not straightforward and has not specifically been targeted, with therapeutic strategies only comprising interventions with appetite stimulants, and anti-inflammatory substances. Here we review the molecular pathways underlying CC-related muscle wasting aiming to provide clues for the definition of CC-specific biomarkers and for the development of drugs that prevent and/or counteract muscle impairment, which will certainly impact the management of cardiovascular disorders.
© 2013.

Entities:  

Keywords:  4E-BP1; ACE; ANP; Angiotensin-converting enzyme; Atrial natriuretic peptide; BMD; BMI; BNP; Body mass index; Bone mineral density; Brain natriuretic peptide; CC; CHF; CT; Cardiac cachexia; Chronic heart failure; Computed tomography; Constitutive nitric oxide synthase; DHEA; Dehydroepiandrosterone; ESR; Erythrocyte sedimentation rate; Eukaryotic translation initiation factor 4E binding protein; FOXO; Forkhead box O; GC; GFR; GH; Glomerular filtration rate; Glucocorticoids; Growth hormone; HF; Heart failure; IGF; IGFBP-3; IGFBPs; IL-1; IL-10; IL-1β; IL-6; Inhibitor of the eukaryotic translation initiation factor 4E; Insulin-like growth factor; Insulin-like growth factor binding protein 3; Insulin-like growth factor binding proteins; Interleukin 1; Interleukin 1 beta; Interleukin 10; Interleukin 6; LPS; MRI; Magnetic resonance imaging; Mechanisms; N-terminal pro-BNP; NOS; NPS; NT-proBNP; Natriuretic peptide system; Nitric oxide synthase; PI3K; PNS; PRA; Parasympathetic nervous system; Phosphatidylinositol 3-kinase; Plasma renin activity; RAAS; ROS; Reactive oxygen species; Renin–angiotensin–aldosterone system; SNS; Soluble form of tumor necrosis factor receptor; Sympathetic nervous system; TGF-β1; TNF-α; TNFRs; Transforming growth factor beta 1; Tumor necrosis factor alpha; Tumor necrosis growth factor receptors; UPP; Ubiquitin–proteasome pathway; cNOS; eIF-4E; lipopolysaccharide; p70 ribosomal protein S6 kinase 1; p70S6K1; sTNFR

Mesh:

Substances:

Year:  2013        PMID: 24184665     DOI: 10.1016/j.clinbiochem.2013.10.025

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  16 in total

Review 1.  Publication trends in cachexia and sarcopenia in elderly heart failure patients.

Authors:  Jochen Springer; Stefan D Anker
Journal:  Wien Klin Wochenschr       Date:  2016-11-24       Impact factor: 1.704

Review 2.  Molecular mechanism of sarcopenia and cachexia: recent research advances.

Authors:  Kunihiro Sakuma; Wataru Aoi; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2017-01-19       Impact factor: 3.657

3.  The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.

Authors:  Karyn E O'Connell; Wen Guo; Carlo Serra; Matthew Beck; Lynn Wachtman; Amber Hoggatt; Dongling Xia; Chris Pearson; Heather Knight; Micheal O'Connell; Andrew D Miller; Susan V Westmoreland; Shalender Bhasin
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

Review 4.  Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators?

Authors:  Rita Nogueira-Ferreira; Fábio Sousa-Nunes; Adelino Leite-Moreira; Liliana Moreira-Costa; Rui Vitorino; Lúcio Lara Santos; Daniel Moreira-Gonçalves; Rita Ferreira
Journal:  Inflamm Res       Date:  2022-06-09       Impact factor: 6.986

Review 5.  Sympathetic activation in congestive heart failure: an updated overview.

Authors:  Guido Grassi; Fosca Quarti-Trevano; Murray D Esler
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

6.  The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia.

Authors:  Federica Calore; Priya Londhe; Paolo Fadda; Giovanni Nigita; Lucia Casadei; Gioacchino Paolo Marceca; Matteo Fassan; Francesca Lovat; Pierluigi Gasparini; Lara Rizzotto; Nicola Zanesi; Devine Jackson; Svasti Mehta; Patrick Nana-Sinkam; Deepa Sampath; Raphael E Pollock; Denis C Guttridge; Carlo M Croce
Journal:  Cancer Res       Date:  2018-09-12       Impact factor: 12.701

Review 7.  Emerging biomarkers in heart failure and cardiac cachexia.

Authors:  Goran Loncar; Daniel Omersa; Natasa Cvetinovic; Aleksandra Arandjelovic; Mitja Lainscak
Journal:  Int J Mol Sci       Date:  2014-12-22       Impact factor: 5.923

8.  N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for Loss of Muscle Mass in Prevalent Hemodialysis Patients.

Authors:  Misa Ikeda; Hirokazu Honda; Keiko Takahashi; Kanji Shishido; Takanori Shibata
Journal:  PLoS One       Date:  2016-11-21       Impact factor: 3.240

9.  A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart.

Authors:  Valentina Sala; Stefano Gatti; Simona Gallo; Enzo Medico; Daniela Cantarella; James Cimino; Antonio Ponzetto; Tiziana Crepaldi
Journal:  Biomed Res Int       Date:  2016-05-19       Impact factor: 3.411

Review 10.  Cardiac cachexia: hic et nunc.

Authors:  Goran Loncar; Jochen Springer; Markus Anker; Wolfram Doehner; Mitja Lainscak
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-07-01       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.